ClinicalTrials.gg
CompletedNCT00911534Updated Feb 2, 2016Results posted

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

A Phase 3 interventional study of rabeprazole sodium and Placebo in Symptomatic Gastroesophageal Reflux Disease (sGERD), sponsored by Eisai Inc.. Completed at 98 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-02.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
9th of 39
305 · median 100
Started
2009
with 3 others
Phase 3
16 of 40
none open now
Registered
30th of 40
by date
Lead sponsor
9 of 40
Eisai Inc.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 9th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2009, is one of 16 in phase 3, and was the 30th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).

03

Conditions studied

  • Symptomatic Gastroesophageal Reflux Disease (sGERD)

Keywords

  • Gastroesophageal Reflux Disease
  • GERD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY INCLUSION CRITERIA:

Male or female, ages 18 through 75 years will be included in the study. Females should be either of nonchildbearing potential or of . Females of childbearing potential must have negative serum and urine pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of starting at Visit 1 and throughout the entire study period and for 1 month after the last dose of study drug. Women using hormonal contraceptives must also be using an additional approved method of contraception starting at Visit 1 and throughout the entire study period and for 1 month after the last dose of study drug. Pregnant or lactating females are excluded. Subjects must have a history of heartburn, identified as their main complaint, for 6 months or longer.Subjects must have documentation of a minimum of 5 moderate to severe heartburn episodes, 3 of which occur during the daytime and 1 of which occurs during the nighttime, during the last 7 days before randomization. Subjects must be able to read, write, and understand the language of the symptom dairy.

KEY EXCLUSION CRITERIA:

Subjects will be excluded from the study if they are found to have erosive esophagitis during esophagogastroduodenoscopy (EGD) at Screening, current or a history of esophageal motility disorders, current or a history of Barrett's esophagus, current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications), current or a history of Zollinger-Ellison syndrome and acid hypersecretory conditions, or current gastric or duodenal ulcer. Subjects will be excluded if they are found to have current or a history of cancer, with the exception of fully excised skin basal cell carcinoma, inflammatory bowel disease, a history of esophageal, gastric and duodenal surgery, except simple closure of a perforated ulcer. Subjects will be excluded who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral (>=20 mg/day prednisone or equivalent), or aspirin (>325 mg/day). Female subjects will be excluded who are pregnant, lactating, or have a positive B-human gonadotropin test at Screening/Baseline. Subjects will be excluded who are known to be (HIV) positive, have participated in another drug study within 30 days prior to screening or are expected to receive an investigational drug during this trial. Subjects who are unwilling to provide will be excluded.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    1

    Drug: rabeprazole sodium

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.

    Also known as: rabeprazole sodium extended release

  • DrugPlacebo

    One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.

06

What researchers measure

Primary outcomes

  1. Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4

    Participants completed a daily symptom diary. A heartburn-free day was defined as participant report of 'No Heartburn' from nighttime and daytime of the diary for the same day.

    Time frame: Week 4

Secondary outcomes

  1. Change From Baseline in Average Daily Severity Score of Gastroesophageal Reflux Disease (GERD)-Related Symptoms at Week 4

    Participants collected GERD-associated symptoms of daytime heartburn, nighttime heartburn and regurgitation in daily symptom diary. Daytime episodes were defined as those that occurred after arising in the morning until retiring in the evening, and nighttime episodes were defined as those that occurred during the night while sleeping or trying to sleep. The severity score was calculated was based on a 5-point Likert scale ranging from 0 (no symptom) to 4 (very severe symptom); higher scores indicated greater disease activity.

    Time frame: Baseline and Week 4

Other outcomes

  1. Percentage of Participants With Complete Heartburn Relief

    Participants completed a daily symptom diary.

    Time frame: Week 2 and Week 4

  2. Time to Achieve First 24-Hour Period Without Heartburn

    Participants completed a daily symptom diary.

    Time frame: Baseline to Week 4

07

Results

Posted Feb 2, 2016

Participant flow

Participant flow — Overall Study
MilestonePlaceboRAB ER 50mg
Started147153
Completed132137
Not completed1516
Withdrew: Adverse event44
Withdrew: Lost to follow-up24
Withdrew: Withdrawal by subject21
Withdrew: Lack of efficacy41
Withdrew: Withdrawal of consent14
Withdrew: Other22

Outcome measures

SecondaryChange From Baseline in Average Daily Severity Score of Gastroesophageal Reflux Disease (GERD)-Related Symptoms at Week 4

Participants collected GERD-associated symptoms of daytime heartburn, nighttime heartburn and regurgitation in daily symptom diary. Daytime episodes were defined as those that occurred after arising in the morning until retiring in the evening, and nighttime episodes were defined as those that occurred during the night while sleeping or trying to sleep. The severity score was calculated was based on a 5-point Likert scale ranging from 0 (no symptom) to 4 (very severe symptom); higher scores indicated greater disease activity.

Time frame:
Baseline and Week 4
Reported as:
Mean · Scores on a Scale
Change From Baseline in Average Daily Severity Score of Gastroesophageal Reflux Disease (GERD)-Related Symptoms at Week 4
Scores on a ScalePlaceboRAB ER 50mg
Heartburn (Daytime)-0.82 ± 0.65-1.22 ± 0.79
Heartburn (Nighttime)-0.74 ± 0.72-1.17 ± 0.78
Regurgitation-0.49 ± 0.62-0.74 ± 0.81
PrimaryMean Percentage of Diary-Recorded Heartburn-Free Days at Week 4

Participants completed a daily symptom diary. A heartburn-free day was defined as participant report of 'No Heartburn' from nighttime and daytime of the diary for the same day.

Time frame:
Week 4
Reported as:
Mean · Percentage of Days
Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4
Percentage of DaysPlaceboRAB ER 50mg
Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 421.23 ± 26.841.14 ± 34.49
Other pre-specifiedPercentage of Participants With Complete Heartburn Relief

Participants completed a daily symptom diary.

Time frame:
Week 2 and Week 4
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete Heartburn Relief
Percentage of ParticipantsPlaceboRAB ER 50mg
Week 2 (n=147, 148)3.415
Week 4 (n=147, 148)7.522.2
Other pre-specifiedTime to Achieve First 24-Hour Period Without Heartburn

Participants completed a daily symptom diary.

Time frame:
Baseline to Week 4
Reported as:
Mean · Days
Time to Achieve First 24-Hour Period Without Heartburn
DaysPlaceboRAB ER 50mg
Time to Achieve First 24-Hour Period Without Heartburn14.4 ± 0.8410.6 ± 0.92

Adverse events

Collected over For each participant, from the time participant signed the study consent form until resolution or for up to 30 days after study drug discontinuation, whichever came first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/147 (0.7%)0/147 (0%)
RAB ER 50mg—0/152 (0%)0/152 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboRAB ER 50mg
Cholecystitis, acuteHepatobiliary disorders1/1470/152

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboRAB ER 50mgTotal
Mean44.4 ± 13.3243.8 ± 12.3544.1 ± 12.82
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRAB ER 50mgTotal
Female103105208
Male444892
08

Study locations

98 sites
  • Athens, Alabama 35611, United States
  • Huntsville, Alabama 35801, United States
  • Tucson, Arizona 85712, United States
  • Little Rock, Arkansas 72205, United States
  • Anaheim, California 92801, United States
  • Encinitas, California 92024, United States
  • Irvine, California 92618, United States
  • Lancaster, California 93534, United States
  • Los Angeles, California 90301, United States
  • Merced, California 95340, United States
  • Oceanside, California 92056, United States
  • Orange, California 92869, United States
  • Pasadena, California 91105, United States
  • Sacramento, California 95823, United States
  • San Diego, California 92103, United States
  • San Diego, California 92117, United States
  • San Diego, California 92123, United States
  • Wheat Ridge, Colorado 80033, United States
  • Bridgeport, Connecticut 6606, United States
  • Altamonte Springs, Florida 32701, United States
  • Boynton Beach, Florida 33437, United States
  • Cape Coral, Florida 33904, United States
  • Hialeah, Florida 33012, United States
  • Miami, Florida 33133, United States
  • Miami, Florida 33143, United States
  • Miami, Florida 33144, United States
  • New Smyrna Beach, Florida 32168, United States
  • Orlando, Florida 32806, United States
  • Tampa, Florida 33613, United States
  • Wellington, Florida 33414, United States
  • Zephyrhills, Florida 33542, United States
  • Decatur, Georgia 30033, United States
  • Newnam, Georgia 30263, United States
  • Chicago, Illinois 60622, United States
  • Evansville, Indiana 47714, United States
  • Wichita, Kansas 67203, United States
  • Wichita, Kansas 67207, United States
  • Lake Charles, Louisiana 70601, United States
  • Metairie, Louisiana 70006, United States
  • Shreveport, Louisiana 71103, United States
  • Hagerstown, Maryland 21742, United States
  • Hollywood, Maryland 20636, United States
  • Chesterfield, Michigan 48047, United States
  • Troy, Michigan 48098, United States
  • Chaska, Minnesota 55318, United States
  • Mexico, Missouri 65265, United States
  • Butte, Montana 59701, United States
  • Haddon Heights, New Jersey 8035, United States
  • Ocean, New Jersey 7712, United States
  • Vineland, New Jersey 8360, United States
  • Voorhees, New Jersey 8043, United States
  • Great neck, New York 11021, United States
  • Great Neck, New York 11023, United States
  • Lake Success, New York 11042, United States
  • Pittsford, New York 14534, United States
  • Rochester, New York 14609, United States
  • Asheville, North Carolina 28801, United States
  • Boone, North Carolina 28607, United States
  • Charlotte, North Carolina 28209, United States
  • Durham, North Carolina 277'13, United States
  • Fayetteville, North Carolina 28304, United States
  • Greesnboro, North Carolina 27265, United States
  • High Point, North Carolina 27262, United States
  • Jacksonville, North Carolina 28546, United States
  • Kinston, North Carolina 28501, United States
  • New Bern, North Carolina 28562, United States
  • Raleigh, North Carolina 27612, United States
  • Rutherford College, North Carolina 28671, United States
  • Cincinnati, Ohio 45219, United States
  • Gallipolis, Ohio 45631, United States
  • Mentor, Ohio 44060, United States
  • Perrysburg, Ohio 43551, United States
  • Norman, Oklahoma 73071, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Charleston, South Carolina 29414, United States
  • Simpsonville, South Carolina 29681, United States
  • Franklin, Tennessee 37067, United States
  • Jackson, Tennessee 38301, United States
  • Johnson City, Tennessee 37604, United States
  • Joshson City, Tennessee 37601, United States
  • Nashville, Tennessee 37203, United States
  • Nashville, Tennessee 37211, United States
  • Corsicana, Texas 75110, United States
  • Houston, Texas 77030, United States
  • Houston, Texas 77090, United States
  • Laredo, Texas 78041, United States
  • Odessa, Texas 79761, United States
  • Overland Park, Texas 66215, United States
  • San Antonio, Texas 78229, United States
  • Sugar Land, Texas 77479, United States
  • Bountiful, Utah 84010, United States
  • Ogden, Utah 84405, United States
  • West Valley City, Utah 84120, United States
  • Charlottesville, Virginia 22911, United States
  • Christiansburg, Virginia 24073, United States
  • Madison, Wisconsin 53715, United States
  • Milwaukee, Wisconsin 53209, United States
  • Monroe, Wisconsin 53566, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jul 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 6 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2009
First posted
Jun 2, 2009
Start
Jan 2009
Primary completionActual
Jul 2009
CompletionActual
Oct 2009
Results first posted
Feb 2, 2016
Last update
Feb 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00911534
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 2, 2009
Start date
Jan 2009
Primary completion
Jul 2009
Completion
Oct 2009
Results posted
Feb 2, 2016
Last update
Feb 2, 2016

Study contacts

Guillermo Rossiter, MD
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion